With Geron Deal Done, AngioChem Turns To Its Own Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.